UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 27, 2016
Illumina, Inc.
(Exact name of registrant as specified in its charter)

001-35406
(Commission File Number)

 
 
 
 
 
 
Delaware
 
33-0804655
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122
(Address of principal executive offices) (Zip code)

(858) 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective as of January 27, 2016, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from 10 to 11 members and elected Frances Arnold, Ph.D., to serve on the Board.  Dr. Arnold has been assigned to serve in the class of directors standing for election at the Company’s 2016 annual meeting of stockholders, which currently includes Francis deSouza and David Walt, and, consistent with the Company’s Corporate Governance Guidelines, Dr. Arnold will stand for election by the Company’s stockholders at the Company’s 2016 annual meeting of stockholders to serve for a three-year term commencing with such meeting.  There is no arrangement or understanding between Dr. Arnold and any other person pursuant to which she was selected as a director.  In addition, Dr. Arnold is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933.  Dr. Arnold will participate in the non-employee director compensation programs described under "Director Compensation" in the Company's proxy statement filed on April 8, 2015.  A copy of the Company's press release announcing Dr. Arnold’s appointment is filed as Exhibit 99.1 to this Form 8-K.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1    Press release dated January 28, 2016 announcing the appointment of Dr. Frances Arnold to its Board of Directors.




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 
 
 
 
 
 
 
ILLUMINA, INC.
 
Date:
January 28, 2016
By:  
/s/ CHARLES E. DADSWELL
 
 
 
Charles E. Dadswell
 
 
 
Senior Vice President, General Counsel and Secretary






Illumina Appoints Dr. Frances Arnold to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)-Jan 28, 2016- Illumina, Inc. (NASDAQ: ILMN) today announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.

Dr. Arnold joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor and Director. Her laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals and medicine.
 
“We are very pleased to welcome Dr. Arnold to our board and look forward to leveraging her experience and expertise in life sciences and medicine,” said Jay Flatley, Illumina Chief Executive Officer. “We value the perspective and passion that she will bring to the role as we plan for growth in our clinical and research markets.”

Dr. Arnold is the recipient of numerous honors, including induction into the National Inventors Hall of Fame (2014), Fellow of the National Academy of Inventors (2014), the ENI Prize in Renewable and Nonconventional Energy (2013), the US National Medal of Technology and Innovation (2011), and the Charles Stark Draper Prize of the US National Academy of Engineering (2011). She has been elected to membership in all three US National Academies, of Science, Medicine, and Engineering and the American Academy of Arts and Sciences.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com


Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Illumina Charts.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Illumina Charts.